(Q39730284)

14 September 2017

1 reference

title

Antibacterial therapy. (English)

1 reference

14 September 2017

Feingold DS

1

1 reference

14 September 2017

Wagner RF Jr

series ordinal

2

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 April 1986

1 reference

Journal of the American Academy of Dermatology

14 September 2017

published in

1 reference

14 September 2017

volume

14

1 reference

14 September 2017

issue

4

1 reference

14 September 2017

page(s)

535-548

1 reference

Dermatologic training for nondermatologists

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Penicillin Hypersensitivity—A Review

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Penicillin allergy--can the incidence be reduced?

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Treatment of bacterial endocarditis in patients with penicillin hypersensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Penicillin allergy and desensitization in serious infections during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Adverse Reactions Associated with the Use of Oral Penicillins and Cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Treatment of staphylococcal skin infections: a comparison of cephalexin and dicloxacillin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Comparison of in vitro antibacterial activity of three oral cephalosporins: cefaclor, cephalexin, and cephradine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Drug therapy: The newer cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Clavulanic Acid, a Novel Inhibitor of β-Lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Clindamycin in the treatment of soft tissue infections: a review of 15 019 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Prolongation of a pancuronium-induced neuromuscular blockade by clindamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

FATAL LIVER DISEASE AFTER INTRAVENOUS ADMINISTRATION OF TETRACYCLINE IN HIGH DOSAGE

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Effects of trimethoprim on folate metabolism in man

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Trimethoprim-sulfamethoxazole in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Trimethoprim, a sulphonamide potentiator

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Therapy of gonorrhea. Comparison of trimethoprim-sulfamethoxazole and ampicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Trimethoprim-sulfamethoxazole: an assessment of more than 12 years of use.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Sulphonamides and trimethoprim

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

History of the Development of Rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

1 reference

7 January 2021

The Antimicrobial Activity of Rifampin: Emphasis on the Relation to Phagocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Concurrent steroid and rifampicin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Toxicologic and pharmacologic aspects of rifampin.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Long-term studies of the effect of rifampin on nasal carriage of coagulase-positive staphylococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Short-course and single-dose antimicrobial therapy for chancroid in Kenya: studies with rifampin alone and in combination with trimethoprim.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Rifampin therapy for brucellosis, flavobacterium meningitis, and cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Adverse Effects of Rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Rifampicin Overdosage—The Red Man Syndrome'

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Rifampin: a suicidal dose

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Interaction of rifampin and chlorpropamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

1 reference

7 January 2021

Nonspecific vaginitis: role of Haemophilus vaginalis and treatment with metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Artifactual Depression of Serum Glutamic Oxaloacetic Transaminase by Metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Toxicity of Disulfiram Combined with Metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

The stereoselective interaction of warfarin and metronidazole in man

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals: discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Lack of evidence for cancer due to use of metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Cancer after metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

1 reference

7 January 2021

Activities of new quinoline derivatives against genital pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

Treatment of Penicillin-ResistantNeisseria gonorrhoeaewith Oral Norfloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2886%2980441-8

7 January 2021

10.1016/S0190-9622(86)80441-8

Identifiers

DOI

1 reference

14 September 2017

1 reference